France / CIS 65545895

OSELTAMIVIR ZENTIVA 75 mg, gélule

gélule · orale

Directory source checks passedOriginal source language: French

Source data retrieved: 2026-09-17. Clinical review is not yet available.

Formgélule
Routeorale
Ingredient entries2
CountryFrance

Product identity

At a glance

Authorisation holder
ZENTIVA FRANCE
Authorisation status
Autorisation active
Market status
Commercialisée
Country
France
Source reference
CIS 65545895

Reported market status does not confirm current pharmacy stock.

From the official composition record

Ingredients & strength

Source entries are shown individually. An active substance (SA) and its reference moiety (FT) may describe the same ingredient; do not add their strengths together.

Source composition entries for OSELTAMIVIR ZENTIVA 75 mg, gélule
IngredientStrength / referenceSource role
PHOSPHATE D'OSÉLTAMIVIRgélule98,50 mgune géluleSAGroup 1
OSÉLTAMIVIRgélule75 mgune géluleFTGroup 1

Pack references

Presentations (1)

plaquette(s) PVC polyéthylène PVDC aluminium de 10 gélule(s)

CIP13 3400930205365

Présentation active · Déclaration de commercialisation

From the French medicines authority

Official documents

The official product entry provides access to the patient leaflet and professional product information when available. Documents are in French and availability varies by medicine.

Open the official product entryBDPM · CIS 65545895 · Opens in a new tab

Check the medicine name, strength and form against your pack. The authority’s current documents may be newer than the catalogue snapshot shown here.

Where this information comes from

Sources & dates

Base de données publique des médicaments (BDPM), France. Retrieval dates record when we obtained the source files; they are not clinical review dates or a guarantee of current stock.

Source files and their retrieval dates
Source fileRetrievedSource file modified
fr_products.txtNot supplied
fr_composition.txtNot supplied
fr_packs.txtNot supplied

Directory source checks cover the factual catalogue record.Molindra clinical guidance has not yet been reviewed or published for this medicine.

Our sources and review process →